--- title: "Carlyle's Q1 2026 13F Is a PE Exit Pipeline in Plain View" type: research slug: carlyle-group-q1-2026-13f-medline-standardaero-pe-exit canonical_url: https://13finsight.com/research/carlyle-group-q1-2026-13f-medline-standardaero-pe-exit published_at: 2026-05-11T06:59:45.525Z updated_at: 2026-05-11T06:59:48.672Z author: Marcus Chen author_title: Senior Market Analyst author_url: https://13finsight.com/authors/marcus-chen word_count: 1083 locale: en source: 13F Insight --- # Carlyle's Q1 2026 13F Is a PE Exit Pipeline in Plain View > Carlyle Group's Q1 2026 13F is a $10.62B portfolio where Medline and StandardAero alone account for 99.0% of disclosed value. The filing is best read as a PE exit pipeline tracker, not a public-equity research book. Carlyle Group Inc.'s Q1 2026 13F discloses a $10.62 billion public-equity book — and 78.4% of that book sits in a single name: Medline Industries (MDLN). Add StandardAero (SARO) at 20.58% and the top two positions are 99.0% of the entire reported value. The remaining 18 holdings — Phathom Pharmaceuticals, Pony AI, Invitation Homes, CubeSmart, Krispy Kreme, Robinhood, and a tail of micro-cap and post-SPAC names — together account for less than 1% of the portfolio.This is not a 13F that needs to be read like a portfolio. It needs to be read like a private-equity exit register: post-IPO retained equity from large, recent Carlyle-led buyouts, sitting on the public ledger while distribution to limited partners works through lockup expirations and orderly disposition windows. The differentiated angle this quarter is that the AUM compression from Q4 2025 ($13.57B) to Q1 2026 ($10.62B) — a roughly $3 billion drop — happened with the holdings count unchanged at 20. Carlyle did not exit positions; the marks moved.The 99% Concentration: Two Mega-Buyouts on the Public TapeThe dataset is unusually clean for a 13F because two positions dominate everything else. Medline at $8.33B (187.08M shares) is the larger anchor; StandardAero at $2.18B (84.59M shares) is the second. Carlyle's holding history on these names (consult the firm's public PE-exit timelines) traces back to the consortium-led Medline buyout closed in late 2021 and to the StandardAero refinancing and IPO that followed in 2024. Both companies trade on US exchanges; both are still in their post-IPO lockup-and-distribution phase from a Carlyle perspective.The bar chart above is the cleanest visual representation of what's happening: two skyscrapers and a flat horizon. There is no third position above $40M in the entire 13F. That is structurally what a PE-exit-pipeline 13F looks like — concentrated retained equity from named portfolio companies, with a long tail of small legacy or pre-IPO positions that PE shops carry through their public-securities accounts for various administrative reasons (warrant exercises, secondary distributions, post-SPAC residuals).The QoQ Story Is About Marks, Not TradesThe full AUM history shows the post-IPO trajectory clearly. Carlyle's reported 13F value held below $5B for most of 2024 — the Medline IPO had not yet hit the public tape in size — then stepped up materially through 2025 as the Medline and StandardAero positions came onto the disclosed sleeve. By Q4 2025 the reported value sat at $13.57B; by Q1 2026 it had compressed to $10.62B.That $2.95B drawdown over a single quarter is not Carlyle exiting positions — the holdings count stayed at exactly 20, and the top-two share counts in the disclosed reporting account look essentially flat between filings. The QoQ AUM swing is a mark-to-market artifact: MDLN and SARO both traded materially lower into the quarter end, and at this concentration level even modest price moves on the top two names produce 8-figure AUM swings.This is a structural feature of PE-firm 13Fs. When 99% of disclosed value sits in two positions, the reported number is more sensitive to single-name price action than to portfolio decisions. A retail reader who treats this drawdown as a Carlyle conviction shift would be misreading the form.The Long-Tail Names Are More Interesting Than They LookThe 18 sub-1% positions function as a window into Carlyle's broader PE realization activity rather than as a portfolio in their own right. The names cluster in three buckets:Recent IPO residuals: Robinhood (Carlyle's pre-IPO position), Krispy Kreme (DNUT) (Carlyle-controlled), Pony AI (PONY). These are post-distribution remnants where Carlyle retained sub-1% disclosure thresholds.REIT exposure: Invitation Homes (INVH) and CubeSmart (CUBE) — public-REIT exposure on the order of $8-17M, possibly tied to a Carlyle real-estate strategy or seed positions in REIT-focused funds.Pharma/biotech tail: Phathom Pharmaceuticals (PHAT) at $38.8M is the largest of the small positions, plus QTTB, SYRE, ACET, NABL — small-cap biotech and specialty pharma exposure typical of post-IPO retained equity.None of these warrant standalone analysis at their current weights, but the composition tells you what the firm's current public-securities ledger looks like — heavily anchored by the two big buyouts on top, with a thin distribution-pipeline tail underneath.Forward Read: Watch the Lockup-Distribution CadenceThe right way to read a Carlyle 13F over the next several quarters is to track share count on MDLN and SARO, not the dollar AUM. Three specific signals to watch:Mid-August 2026 13F (Q2 2026): First reportable cycle to confirm whether Carlyle is actively distributing MDLN/SARO to LPs (share-count drop) or just absorbing mark-to-market (share-count flat). The 187.08M MDLN share count is the line that matters; a 5-10% drop would signal distribution acceleration, a flat read would suggest lockup discipline.SARO disposition pace: At $2.18B and 84.59M shares, SARO is the smaller exit position — and the more visible candidate for accelerated distribution because the post-IPO lockup window typically resolves earlier on the smaller deal. Watch StandardAero's float-shares-outstanding ratio in the next 10-Q for the public-side liquidity picture.Tail growth or attrition: A new sub-$50M position appearing in the long tail would suggest Carlyle has another portfolio company approaching IPO or already public; tail attrition (positions falling out below the reporting threshold) suggests current pipeline names are being fully distributed.What This Filing Doesn't Tell You13F coverage is structurally incomplete for PE firms. Carlyle's actual managed AUM is in the hundreds of billions across private equity, real assets, credit, and insurance solutions — none of which appears on the 13F because none of it is in qualifying US-listed equity securities. The $10.62B reported here is just the visible edge of a much larger PE realization machine.For comparable structural reads on other large PE shops with public-equity sleeves dominated by post-IPO retained equity, look at the holder-overlap pattern at Robinhood (where multiple PE shops show small post-IPO residuals) and the broader signal feed at /insights, which surfaces concentrated single-name conviction and distribution patterns across active institutional filers.Bottom LineCarlyle Group's Q1 2026 13F should not be read as a research portfolio. It is a snapshot of a PE realization pipeline at a specific point in time, with two anchor positions (Medline and StandardAero) accounting for 99% of value and a long tail of post-IPO residuals filling out the remaining percent. The Q1 AUM drawdown from $13.57B to $10.62B was a mark-to-market event, not a discretionary trim, and the next meaningful signal will be the share-count delta on MDLN and SARO in the August 2026 13F filing — that's where actual distribution-vs-hold-discipline will become visible.FAQThe full Carlyle Group filer page shows complete holdings history; comparable distribution-pipeline patterns across other large PE shops can be cross-checked via the aggregate signal feed. ## FAQ ### What is in Carlyle Group's Q1 2026 13F filing? Carlyle Group's Q1 2026 13F discloses $10.62 billion across 20 positions. Medline (MDLN) accounts for 78.4% of the portfolio at $8.33B (187.08M shares) and StandardAero (SARO) accounts for 20.58% at $2.18B (84.59M shares). The remaining 18 positions together represent less than 1% of disclosed value. ### Why is Carlyle Group's 13F so concentrated in two stocks? Carlyle is a private-equity firm, not a traditional asset manager. Its 13F discloses public-equity exposure only — primarily retained equity from completed Carlyle-led buyouts that are now publicly traded. The 78.4% Medline and 20.58% StandardAero positions represent post-IPO retained stakes from two of Carlyle's largest recent exits, sitting on the public ledger while distribution to limited partners works through lockup windows. ### Did Carlyle reduce its Medline or StandardAero positions in Q1 2026? Holdings count stayed at exactly 20 positions between Q4 2025 and Q1 2026, with MDLN and SARO share counts essentially flat. The reported AUM compression from $13.57B to $10.62B reflects mark-to-market price moves on those concentrated positions rather than discretionary selling. The next meaningful signal will be share-count deltas on MDLN and SARO in the August 2026 13F filing. ### What does Carlyle Group's actual AUM look like? Carlyle's actual managed AUM is in the hundreds of billions across private equity, real assets, credit, and insurance solutions — none of which appears on the 13F because none of it is in qualifying US-listed equity securities. The $10.62B reported on the Q1 2026 13F is the visible public-equity edge of a much larger PE realization pipeline. --- Source: 13F Insight — https://13finsight.com/research/carlyle-group-q1-2026-13f-medline-standardaero-pe-exit Author: Marcus Chen — https://13finsight.com/authors/marcus-chen Last updated: 2026-05-11T06:59:48.672Z